Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis

Published:2018-05-14 Issue:8 Volume:21 Page:748-757
ISSN:1461-1457
Container-title:International Journal of Neuropsychopharmacology
language:en
Short-container-title:

Author:

Kishi Taro¹,Ikuta Toshikazu²,Oya Kazuto¹,Matsunaga Shinji¹³,Matsuda Yuki⁴,Iwata Nakao¹

Affiliation:

1. Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan

2. Department of Communication Sciences and Disorders, School of Applied Sciences, University of Mississippi, MS USA

3. Department of Department of Geriatrics and Cognitive Disorders, Fujita Health University School of Medicine, Aichi, Japan

4. Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology

Link

http://academic.oup.com/ijnp/article-pdf/21/8/748/25368855/pyy045.pdf

Reference44 articles.

1. Allen T , McEvoyJ, KeefeR(2003)Galantamine as an adjunctive therapy in the treatment of schizophrenia. Paper presented at: 11th Congress of the International Psychogeriatric Association (IPA); August 17–22, 2003; Chicago, IL.

2. Negative symptoms in schizophrenia. Definition and reliability;Andreasen;Arch Gen Psychiatry,1982

3. Cognitive impairment in elderly schizophrenia: a dementia (still) lacking distinctive histopathology;Arnold;Schizophr Bull,1996

4. A randomized clinical trial of oxytocin or galantamine for the treatment of negative symptoms and cognitive impairments in people with schizophrenia;Buchanan;J Clin Psychopharmacol,2017

5. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy;Choi;Br J Psychiatry,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Finding the right dose: NMDAR modulating treatments for cognitive and plasticity deficits in schizophrenia and the role of pharmacodynamic target engagement;Biological Psychiatry;2024-08

2. The schizophrenia syndrome, circa 2024: What we know and how that informs its nature;Schizophrenia Research;2024-02

3. Social Cognitive Impairments as a Target of Non-Invasive Brain Stimulation for Functional Outcomes in Schizophrenia;Oxytocin and Social Function;2024-01-24

4. Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives;Schizophrenia Bulletin Open;2024-01-01

5. Activation of prefrontal parvalbumin interneurons ameliorates working memory deficit even under clinically comparable antipsychotic treatment in a mouse model of schizophrenia;Neuropsychopharmacology;2023-12-04